Harrow Inc (HROW) said after close Tuesday that it lost $0.2 per share in quarter four 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.
On the revenue line, the company reported $36.4 million, missing estimates by $1.5 million.
In the same quarter a year ago, the company earned $0.07 per share on revenue of $20.3 million.
The stock is down 7.98% to $9.80 after the report.
Despite revenues increasing, earnings decreased, signaling a decline in profit margins.
The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.
Trading in the five days leading up to the report earned Harrow Inc a Bullish Sentiment Rank from InvestorsObserver.
Harrow Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 19, putting Harrow Inc in the bottom 25% of stocks. The firm set a 52-week low on November 14, 2023 at $7.6 and set a 52-week high on May 10, 2023 at $28.25.
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
News Home
Harrow Inc Down 7.98% To $9.80 After Earnings Miss
Mentioned in this article
